Syngene International

Price chart

Previous close

₹434.70

Open

₹427.60

Day high

₹444.00

Day low

₹423.90

Listed on NSE since 11 August 2015.

Market value

₹16,772 Cr

P/E (trailing)

90.32

EPS (trailing)

₹4.62

Price to book

3.46

Dividend yield

0.30%

Return on equity

3.9%

Debt to equity

0.10

Profit margin

5.3%

Beta

0.04

Volume today

7.67 L

Average volume

12.92 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Syngene International’s results filed with NSE, consolidated (the whole group). Net profit is the share of Syngene International’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Syngene International’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Industry

Diagnostics & Research

Based in

Bengaluru

Employees

6,692

Company website · Profile: Yahoo Finance

No headlines name Syngene International in the last day or two.

• Dividend - Rs 1.25 Per Share

  Dividend · ex-date 25 June 2026 · record date 26 June 2026

• Dividend - Rs 1.25 Per Share

  Dividend · ex-date 27 June 2025

• Dividend - Rs 1.25 Per Share

  Dividend · ex-date 28 June 2024

• Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share

  Dividend · ex-date 30 June 2023

• Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.50 Per Share

  Dividend · ex-date 30 June 2022 · record date 1 July 2022

• Annual General Meeting

  Action · ex-date 13 July 2021 · record date 14 July 2021

• Dividend - Rs 0.50 Per Share

  Dividend · ex-date 16 July 2019 · record date 17 July 2019

• Bonus 1:1

  Bonu · ex-date 11 June 2019 · record date 12 June 2019

Source: NSE. Latest first, 8 of 11.